Bedel LUKOKI BEUDIN

Dr. Bedel LUKOKI BEUDIN

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2026 in Renal Failure
Verified
Journal Article
Open access
YEYannick Mompango Engole
Yannick Mompango Engole
JMJean-Robert Rissassy Makulo
Jean-Robert Rissassy Makulo
YNYannick Mayamba Nlandu
Yannick Mayamba Nlandu
ANAliocha Nkodila
Aliocha Nkodila
JBJustine Bukabau
Justine Bukabau
EKErnest SUMAILI KISWAYA
Ernest SUMAILI KISWAYA
Sickle cell disease (SCD) is the most common monogenic hemoglobinopathy worldwide, affecting approximately 300,000 newborns annually, with the highest burden in sub-Saharan Africa, India, the Middl...

4 January 2026 in Diseases
Verified
Journal Article
Open access
PDF file
BBBedel LUKOKI BEUDIN
Bedel LUKOKI BEUDIN
TKTchilabalo Kakomkate
Tchilabalo Kakomkate
WIWahiba Ibeghouchene
Wahiba Ibeghouchene
CCCéline Carreira
Céline Carreira
IOImene Ouertani
Imene Ouertani
JBJustine Bukabau
Justine Bukabau
Background and Objectives: On-line hemodiafiltration (OL-HDF) has been proposed as an alternative to conventional hemodialysis (HD) for patients with end-stage chronic kidney disease (CKD). Randomized controlled trials suggest that OL-HDF may reduce mortality, particularly when the convection volume (CV) exceeds 23 L/1.73 m2 per session. However, achieving this target depends on local practices and may be limited to selected populations. The CONVINCE trial reported a 97% success rate using a structured optimization protocol, but its applicability to unselected real-world populations remains uncertain. This study aimed to evaluate the incidence of high CV in OL-HDF among unselected patients managed under routine conditions with a standardized optimization protocol. Methods and Materials: This prospective cohort study (May–October 2024) included 67 unselected incident and prevalent patients undergoing HD or HDF in a hospital-based dialysis center. All patients were switched to post-dilution OL-HDF following the CONVINCE optimization protocol, which involved stepwise increases in blood flow, adjustment of filtration fraction, and optimization of session duration. Results: The mean age was 68.8 ± 14.9 years; 56.7% were male. Blood flow increased from 283 to 338 mL/min (p < 0.001), and the use of dialyzers > 2 m2 increased from 36% to 68% (p < 0.003). Kt/V improved from 1.22 to 1.6 (p < 0.01). CV increased by ~2 L from M1 onward and was sustained through M6, correlating positively with blood flow, session duration, and Kt/V (all p < 0.01). Conclusions: Stepwise optimization protocol enabled sustained achievement of high CV (23.5 L/session) in 62.3% of patients, improving dialysis adequacy.